Research programme: stem cell therapies - MedImmune/University System of Maryland

Drug Profile

Research programme: stem cell therapies - MedImmune/University System of Maryland

Latest Information Update: 08 May 2014

Price : $50

At a glance

  • Originator MedImmune; University System of Maryland
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Cardiovascular disorders; Metabolic disorders

Most Recent Events

  • 08 May 2014 Early research in Metabolic disorders in USA (unspecified route)
  • 08 May 2014 Early research in Cardiovascular disorders in USA (unspecified route)
  • 29 Apr 2014 MedImmune and University System of Maryland agree to co-develop stem cell therapies in USA for cardiovascular and Metabolic disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top